Article Text

PDF
Naltrexone increased abstinence and reduced heavy drinking during treatment

Statistics from Altmetric.com


 
 Q In people with alcohol dependence, is medical management with naltrexone, acamprosate, or both, with or without the addition of a combined behaviour intervention (CBI), effective for increasing abstinence or decreasing heavy drinking?

Clinical impact ratings GP/FP/Mental health ★★★★★★☆ Psychiatry ★★★★★☆☆

METHODS

Embedded ImageDesign:

randomised placebo controlled trial (Combined Pharmacotherapies and Behavioral Interventions [COMBINE] study).

Embedded ImageAllocation:

concealed.*

Embedded ImageBlinding:

blinded (patients, healthcare providers, research staff, and outcome assessors were blinded to medication assignment).*

Embedded ImageFollow up period:

16 weeks and 1 year.

Embedded ImageSetting:

11 academic sites in the US.

Embedded ImagePatients:

1383 patients (median age 44 y, 69% men) who met DSM-IV criteria for alcohol dependence, had been abstinent for 4–21 days, and consumed >14 (women) or >21 (men) drinks weekly with ⩾2 heavy drinking days (ie, ⩾4 drinks/d for women, ⩾5 drinks/d for men) during a consecutive 30 day period in the previous 90 days. Exclusion criteria included other substance abuse (except nicotine or cannabis) in the past 90 days, psychiatric disorder requiring medication, unstable medical conditions, and {certain medications that posed a safety risk}.

Embedded ImageIntervention:

patients were allocated …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Glossary
    BMJ Publishing Group Ltd
  • Other articles noted
    BMJ Publishing Group Ltd